Next 10 |
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1...
2024-03-19 06:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PURE Bioscience (OTCMKTS: PURE ) just reported results for the second quarter of 2024. PURE Bioscience reported earnings per share of -1 cent. The company reported rev...
2024-03-18 16:52:44 ET More on PURE Bioscience Financial information for PURE Bioscience Read the full article on Seeking Alpha For further details see: PURE Bioscience GAAP EPS of -$0.01, revenue of $0.33M
Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial...
Tredegar Corporation (TG) is expected to report for quarter end 2023-12-31 Pharma-Bio Serv Inc (PBSV) is expected to report $0.02 for Q1 2024 Telos Corporation (TLS) is expected to report $-0.18 for Q4 2023 Coretec Group Inc (CRTG) is expected to report for quarter end 2023-12-31 ...
2023-12-18 11:51:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PURE Bioscience (OTCMKTS: PURE ) just reported results for the first quarter of 2024. PURE Bioscience reported earnings per share of -1 cent. The company reported reve...
2023-12-14 17:02:55 ET More on PURE Bioscience Financial information for PURE Bioscience For further details see: PURE Bioscience GAAP EPS of -$0.01, revenue of $0.72M
Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...
2023-10-30 17:32:19 ET More on PURE Bioscience Financial information for PURE Bioscience For further details see: PURE Bioscience GAAP EPS of -$0.04, revenue of $1.87M
News, Short Squeeze, Breakout and More Instantly...
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1...
Update on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial...